• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2024 09

06

The Results of Asandeutertinib Tablets (TY-9591) will be Presented at the WCLC 2024

Discover More
2024 01

04

TYK Medicines Announced First Patient Dosed in Phase 1 clinical trial of its CDK2/4/6 inhibitor TYK-00540

Discover More
2023 09

22

TY-2136b granted Orphan Drug Designation in the US for Non-Small Cell Lung Cancer

Discover More
2023 09

08

TYK Medicine TYK-00540-The first CDK2/4/6 inhibitor in China approved by FDA to conduct clinical trial

Discover More
2023 08

18

TYK Medicines Announces Enrollment of First Patient in Pivotal Phase II Trial of TY-9591 in Treatment of NSCLC with Brain Metastases

Discover More
2023 08

17

TYK Medicines Announced First Patient Dosed in Phase 1 clinical trial of its CDK7 inhibitor TY-2699a

Discover More
12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号